Workflow
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
MyriadMyriad(US:MYGN) GlobeNewswire News Room·2024-06-03 20:05

Core Insights - Myriad Genetics announced the validation of its RiskScore tool for breast cancer risk assessment, published in Genetics in Medicine, which combines a polygenic risk score with the Tyrer-Cuzick model [1][2] Study Overview - The study analyzed outcomes from over 130,000 women who underwent Myriad's MyRisk Hereditary Cancer Test with RiskScore, showing that RiskScore significantly improved predictive accuracy for breast cancer risk compared to the Tyrer-Cuzick model alone, with an approximate two-fold increase in accuracy [2][3] - The study included women tested between 2017-2019 who did not have known pathogenic variants associated with breast cancer and had no prior breast cancer diagnosis [5] Clinical Implications - RiskScore reclassified approximately 1 in 5 women compared to the Tyrer-Cuzick model, potentially leading to better identification of women who may benefit from enhanced surveillance measures [3][4] - The integration of a polygenic risk score for all ancestries into Myriad's precision medicine tool allows for a more comprehensive risk assessment, particularly for women without pathogenic germline mutations [4][5] Company Background - Myriad Genetics is a leader in genetic testing and precision medicine, focusing on advancing health through genetic insights that improve patient care and reduce healthcare costs [6]